Anzeige
Mehr »
Freitag, 03.04.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWA4 | ISIN: GB00BMCLYF79 | Ticker-Symbol: 88Q
Xetra
02.04.26 | 17:35
5,650 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
4BASEBIO PLC Chart 1 Jahr
5-Tage-Chart
4BASEBIO PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,4005,65002.04.
Xetra-Umsätze heute
UhrzeitAktienkursStück

Keine Umsätze verfügbar.

Tagesumsatz Xetra0,000
0,00 %

0

 Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.

Aktuelle News zur Aktie 4BASEBIO PLC

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Mi4BaseBio expands facilities to support growing synthetic DNA demand4
Di4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK1044basebio PLC ("4basebio" or the "Company") Cambridge, UK, 31 March 2026 - 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces...
► Artikel lesen
Di4basebio Plc - Lease of Manufacturing Facility2804basebio Plc - Lease of Manufacturing Facility PR Newswire LONDON, United Kingdom, March 31 4basebio...
► Artikel lesen
4BASEBIO Aktie jetzt für 0€ handeln
12.03.IN BRIEF: 4basebio appoints Scott Lorimer as chief operating officer5
12.03.4basebio Plc - Appointment of COO3614basebio Plc - Appointment of COO PR Newswire LONDON, United Kingdom, March 12 THIS...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Das könnte Sie auch interessieren
ZeitAktuelle NachrichtenMedien
DoCelyad Oncology Reports Full Year 2025 Financial Results and Business HighlightsRegulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update. 2025 business...
► Artikel lesen
DoEQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionEQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide...
► Artikel lesen
DoSharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note OfferingPittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has...
► Artikel lesen
DoOS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth InvestorsCompany expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits...
► Artikel lesen
08:00NurExone baut US-Standbein aus - Exo-Top rückt in den strategischen Fokus